Biomarker pathway heterogeneity of amyloid‐positive individuals is a research paper published in Alzheimer s & Dementia (2024). On theSindex it has a DataRank of 0. It has been cited 6 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Wellcome Trust
Grant: 227341/Z/23/Z
National Institutes of Health
Grant: U01 AG024904
U.S. Department of Defense
Grant: W81XWH‐12‐2‐0012
Department of Defense
Grant: W81XWH-12-2-0012
Wellcome Trust
Grant: 227341
Computational methods for disentangling the effects of mixed pathology in neurodegenerative disease
National Institutes of Health
Grant: 1U01AG024904-01
Alzheimers Disease Neuroimaging Initiative
Canadian Institutes of Health Research
Grant: unidentified
unidentified
Brain Research Trust
Wellcome Trust
Alzheimer's Research UK
Takeda Pharmaceutical Company; Transition Therapeutics
The Wolfson Foundation
Alzheimer's Drug Discovery Foundation
Araclon Biotech
Janssen Alzheimer Immunotherapy Research & Development, LLC
Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC
Alzheimer's Association
BioClinica
Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.
National Institute on Aging
NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier
NIBIB NIH HHS
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
BioClinica, Inc.
Eli Lilly and Company; EuroImmun
National Institute of Biomedical Imaging and Bioengineering
AbbVie
F. Hoffmann-La Roche Ltd; Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.
FWCI
1.70
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords